Clinical Trial Results: Open-label Extension Study of Brazikumab in Ulcerative Colitis [Phase 2]

View source ↗

Summary

Open-label extension study results for brazikumab in ulcerative colitis (Phase 2) have been terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• Brazikumab

Snippet

Sponsor: AstraZeneca | Conditions: Ulcerative Colitis | Phase 2 | Status: TERMINATED | Results posted: 2026-06-23